AUPH
Aurinia Pharmaceuticals Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+1/100
Last price
15.52
▼ 0.21 (1.30%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
15.77
Prev close
15.72
Day high
15.81
Day low
15.47
Volume
698.87K
Market cap
$2.09B
P/E (TTM)
6.88
52W range
10.90 – 19.25
Day trading desk
Gap from prior close
+0.32%
Prior close 15.72
VWAP
15.68
-1.06% from price
Relative volume
1.22×
Normal
Session range
17.24%
14.50 – 17.00
Position in range
41%
Mid range
ATR (14D)
0.35
2.27% of price
Prior day high
15.80
PDH
Prior day low
15.60
PDL
Bid / ask spread
—
Quote not published
Session volume
1.27M
Avg 1.04M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.45%
-6.4%
1M
-2.43%
-3.6%
3M
-3.33%
-7.8%
6M
-0.63%
-18.8%
YTD
-1.63%
-15.9%
1Y
+38.24%
+21.8%
3Y
+101.93%
+19.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AUPH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.13M
Net buying
Buy transactions
4
1.16M shares
Sell transactions
2
32.91K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
9.04M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | ROBERTSON STEPHEN P Officer |
SELL | 11.94K | $190.43K | Direct |
| Aug 21, 26 | ROBERTSON STEPHEN P Officer |
SELL | 20.98K | $355.95K | Direct |
| Jun 2, 26 | TANG KEVIN C Chief Executive Officer |
BUY | 814.61K | $12.46M | Indirect |
| May 18, 26 | HEARNE MICHAEL S. Chief Financial Officer |
STOCK | 116.14K | $0 | Direct |
| May 18, 26 | ROBERTSON STEPHEN P Officer |
STOCK | 115.54K | $0 | Direct |
| May 18, 26 | COLE RYAN Chief Operating Officer |
STOCK | 116.14K | $0 | Direct |
| Mar 3, 26 | TANG KEVIN C Director |
BUY | 900.00K | $12.69M | Indirect |
| Feb 27, 26 | MILLER JOSEPH M Chief Financial Officer |
STOCK | 57.23K | $0 | Direct |
| Feb 27, 26 | GREENLEAF PETER S Chief Executive Officer |
STOCK | 196.40K | $0 | Direct |
| Feb 27, 26 | DONLEY MATTHEW MAXWELL Chief Operating Officer |
STOCK | 58.16K | $0 | Direct |
| Feb 27, 26 | ROBERTSON STEPHEN P General Counsel |
STOCK | 59.09K | $0 | Direct |
| Feb 27, 26 | KEENAN GREGORY M.D. Officer |
STOCK | 40.59K | $0 | Direct |
| Jan 2, 26 | MILLER JOSEPH M Chief Financial Officer |
STOCK | 49.04K | $0 | Direct |
| Jan 2, 26 | GREENLEAF PETER S Chief Executive Officer |
STOCK | 165.38K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAILEY JEFFREY ALLEN |
Director | 25.49K | Stock Award(Grant) |
COLE RYAN |
Chief Operating Officer | 116.14K | Stock Award(Grant) |
DONLEY MATTHEW MAXWELL |
Chief Operating Officer | 680.30K | Stock Award(Grant) |
GREENLEAF PETER S |
Chief Executive Officer | 1.84M | Stock Award(Grant) |
HEARNE MICHAEL S. |
Chief Financial Officer | 116.14K | Stock Award(Grant) |
JAYNE DAVID ROLAND WALKER |
Director | 56.50K | Stock Award(Grant) |
KEENAN GREGORY M.D. |
Officer | 162.52K | Stock Award(Grant) |
MILLER JOSEPH M |
Chief Financial Officer | 576.42K | Stock Award(Grant) |
ROBERTSON STEPHEN P |
Officer | 588.85K | Sale |
TANG KEVIN C |
Chief Executive Officer | — | Purchase |
Fundamentals
Market cap$2.09B
Enterprise value$1.71B
Revenue (TTM)$311.51M
Gross profit$242.61M
EBITDA$179.83M
Net income$314.11M
EPS (TTM)$2.28
Free cash flow$147.82M
Total cash$443.02M
Total debt$64.14M
Book value / share$4.63
Shares outstanding133.05M
Float129.22M
Short % of float7.12%
Dividend yield0.00%
Beta (5Y)1.61
Valuation & profitability ratios
Trailing P/E6.88
Forward P/E14.71
PEG ratio—
Price / sales—
Price / book3.39
EV / revenue5.49
EV / EBITDA9.50
Gross margin77.88%
Operating margin55.68%
Profit margin100.84%
Return on equity66.12%
Return on assets15.49%
Debt / equity10.43
Current ratio5.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $283.06M | $235.13M | $175.51M | $134.03M | — | +20.4% |
| Operating revenue | $283.06M | $235.13M | $175.51M | $134.03M | — | +20.4% |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | — | +15.6% |
| Gross profit | $250.39M | $206.88M | $161.37M | $128.37M | — | +21.0% |
| Research & development | $32.51M | $20.79M | $49.64M | $44.99M | — | +56.4% |
| Selling, general & admin | $101.79M | $172.03M | $195.04M | $196.37M | — | -40.8% |
| Total operating expense | $143.83M | $188.47M | $253.06M | $239.84M | — | -23.7% |
| Operating income | $106.56M | $18.42M | -$91.69M | -$111.47M | — | +478.5% |
| Net interest income | $9.24M | $12.13M | $14.22M | $5.12M | — | -23.8% |
| Pre-tax income | $114.16M | $7.45M | -$77.47M | -$106.35M | — | +1,432.7% |
| Tax provision | -$173.04M | $1.70M | $551.00K | $1.83M | — | -10,303.1% |
| Net income | $287.20M | $5.75M | -$78.02M | -$108.18M | — | +4,893.1% |
| Net income to common | $287.20M | $5.75M | -$78.02M | -$108.18M | — | +4,893.1% |
| Basic EPS | 2.14 | 0.04 | -0.54 | -0.76 | — | +5,250.0% |
| Diluted EPS | 2.07 | 0.04 | -0.54 | -0.76 | — | +5,075.0% |
| EBIT | — | — | — | -$106.35M | -$180.21M | — |
| EBITDA | $137.94M | $31.73M | -$63.05M | -$103.65M | — | +334.7% |
| Basic shares | 134.37M | 143.06M | 143.24M | 141.91M | — | -6.1% |
| Diluted shares | 138.70M | 146.19M | 143.24M | 141.91M | — | -5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $80.21M | $83.43M | $48.88M | $94.17M | -3.9% |
| Cash & short-term investments | $398.00M | $358.48M | $350.49M | $389.39M | +11.0% |
| Accounts receivable | $41.45M | $36.54M | $24.09M | $13.48M | +13.4% |
| Inventory | $45.69M | $39.23M | $39.70M | $24.75M | +16.5% |
| Total current assets | $491.97M | $446.60M | $424.80M | $442.54M | +10.2% |
| Property, plant & equipment | $79.57M | $98.87M | $116.57M | $8.56M | -19.5% |
| Goodwill & intangibles | $3.76M | $4.36M | $4.98M | $6.42M | -13.6% |
| Total assets | $751.59M | $550.64M | $548.06M | $470.86M | +36.5% |
| Total current liabilities | $93.72M | $97.76M | $77.19M | $46.11M | -4.1% |
| Total debt | $74.81M | $79.37M | $97.61M | $8.09M | -5.7% |
| Total liabilities | $170.26M | $173.17M | $170.11M | $65.42M | -1.7% |
| Retained earnings | -$649.37M | -$936.57M | -$942.32M | -$864.30M | +30.7% |
| Shareholder equity | $581.33M | $377.48M | $377.95M | $405.44M | +54.0% |
| Working capital | $398.24M | $348.83M | $347.61M | $396.43M | +14.2% |
| Net tangible assets | $577.57M | $373.12M | $372.98M | $399.01M | +54.8% |
| Shares issued | 132.32M | 140.88M | 143.83M | 142.27M | -6.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $287.20M | $5.75M | -$78.02M | -$108.18M | +4,893.1% |
| Depreciation & amortisation | $19.45M | $19.45M | $11.65M | $2.71M | +0.0% |
| Change in working capital | -$8.78M | $5.45M | -$5.61M | -$6.82M | -261.2% |
| Operating cash flow | $135.66M | $44.39M | -$33.46M | -$79.53M | +205.6% |
| Capital expenditure | -$252.00K | -$281.00K | -$718.00K | -$292.00K | +10.3% |
| Investing cash flow | -$32.77M | $39.26M | -$6.71M | -$60.63M | -183.5% |
| Share buybacks | -$98.16M | -$40.24M | $0 | $0 | -143.9% |
| Financing cash flow | -$106.11M | -$49.09M | -$5.13M | $2.43M | -116.1% |
| Free cash flow | $135.41M | $44.11M | -$34.18M | -$79.82M | +207.0% |
| End cash position | $80.21M | $83.43M | $48.88M | $94.17M | -3.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M | +7.1% |
| Operating revenue | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M | +7.1% |
| Cost of revenue | $6.55M | $6.50M | $8.80M | $8.18M | $7.12M | +0.8% |
| Gross profit | $76.67M | $71.20M | $68.31M | $65.29M | $62.89M | +7.7% |
| Research & development | $13.05M | $7.47M | $10.89M | $8.44M | $7.43M | +74.7% |
| Selling, general & admin | $23.51M | $22.03M | $29.25M | $26.18M | $26.02M | +6.7% |
| Total operating expense | $30.32M | $29.78M | $35.08M | $35.55M | $42.70M | +1.8% |
| Operating income | $46.34M | $41.42M | $33.24M | $29.75M | $20.20M | +11.9% |
| Net interest income | $2.44M | $2.50M | $2.45M | $2.22M | $2.07M | -2.3% |
| Pre-tax income | $48.79M | $43.92M | $35.69M | $31.96M | $22.16M | +11.1% |
| Tax provision | $11.37M | $9.57M | -$175.10M | $411.00K | $643.00K | +18.8% |
| Net income | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | +8.9% |
| Net income to common | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | +8.9% |
| Basic EPS | 0.29 | 0.26 | 1.60 | 0.24 | 0.16 | +11.5% |
| Diluted EPS | 0.28 | 0.25 | 1.53 | 0.23 | 0.16 | +12.0% |
| EBIT | $49.73M | $44.94M | $36.74M | $33.06M | $23.27M | +10.7% |
| EBITDA | $54.57M | $49.75M | $41.60M | $37.93M | $28.14M | +9.7% |
| Basic shares | 130.08M | 132.38M | 131.94M | 131.81M | 134.87M | -1.7% |
| Diluted shares | 133.53M | 137.64M | 138.16M | 136.01M | 137.53M | -3.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $179.83M | $41.01M | $80.21M | $73.19M | $53.00M | +338.5% |
| Cash & short-term investments | $443.12M | $378.78M | $398.00M | $351.81M | $315.13M | +17.0% |
| Accounts receivable | $41.14M | $49.17M | $41.45M | $30.73M | $40.09M | -16.3% |
| Inventory | $45.15M | $46.41M | $45.69M | $44.79M | $46.50M | -2.7% |
| Total current assets | $541.32M | $480.24M | $491.97M | $438.74M | $408.97M | +12.7% |
| Property, plant & equipment | $68.53M | $73.15M | $79.57M | $84.80M | $89.45M | -6.3% |
| Goodwill & intangibles | $3.38M | $3.59M | $3.76M | $3.90M | $4.05M | -5.9% |
| Total assets | $792.26M | $724.00M | $751.59M | $527.53M | $502.56M | +9.4% |
| Total current liabilities | $99.89M | $86.56M | $93.72M | $76.22M | $78.27M | +15.4% |
| Total debt | $64.14M | $68.64M | $74.81M | $78.21M | $81.83M | -6.6% |
| Total liabilities | $177.40M | $156.37M | $170.26M | $161.76M | $167.26M | +13.4% |
| Retained earnings | -$577.60M | -$615.01M | -$649.37M | -$860.16M | -$891.71M | +6.1% |
| Shareholder equity | $614.86M | $567.63M | $581.33M | $365.77M | $335.30M | +8.3% |
| Working capital | $441.43M | $393.69M | $398.24M | $362.52M | $330.70M | +12.1% |
| Net tangible assets | $611.49M | $564.04M | $577.57M | $361.87M | $331.25M | +8.4% |
| Shares issued | 132.91M | 130.77M | 132.32M | 131.84M | 132.67M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | — | +8.9% |
| Depreciation & amortisation | $4.83M | $4.82M | $4.86M | $4.87M | $4.86M | — | +0.4% |
| Stock-based compensation | $2.84M | -$866.00K | $6.73M | $5.92M | $5.44M | — | +427.8% |
| Change in working capital | $1.47M | -$12.87M | $6.50M | $3.97M | $5.73M | — | +111.5% |
| Operating cash flow | $52.57M | $32.56M | $45.67M | $44.45M | $44.24M | — | +61.4% |
| Capital expenditure | — | -$39.00K | -$72.00K | -$65.00K | -$98.00K | -$17.00K | — |
| Investing cash flow | $81.45M | -$18.08M | -$36.76M | -$13.77M | -$13.27M | — | +550.5% |
| Share buybacks | -$38.72M | -$36.16M | $0 | -$8.67M | -$42.56M | — | -7.1% |
| Financing cash flow | $4.81M | -$53.69M | -$1.89M | -$10.49M | -$44.39M | — | +109.0% |
| Free cash flow | $52.57M | $32.52M | $45.60M | $44.38M | $44.14M | — | +61.6% |
| End cash position | $179.83M | $41.01M | $80.21M | $73.19M | $53.00M | — | +338.5% |
Options analytics
Put / call volume
0.81
Call-heavy session
Put / call open interest
0.27
Positioning, not flow
Max pain
12.00
-23.5% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
244
Contracts, this expiry
Put volume
198
Contracts, this expiry
Heaviest call OI
23.00
80 contracts
Heaviest put OI
10.00
23 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.24 | 0.28 | +16.7% |
| Mar 2026 | 0.20 | 0.25 | +26.6% |
| Dec 2025 | 0.22 | 1.53 | +606.1% |
| Sep 2025 | 0.16 | 0.23 | +43.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.22 | 5 | $83.15M | +13.2% |
| Next quarter | 0.20 | 5 | $85.35M | +10.7% |
| Current year | 0.94 | 5 | $329.11M | +16.3% |
| Next year | 1.07 | 6 | $384.40M | +16.8% |
Analyst targets & ownership
Mean target$17.86
High target$21.00
Low target$16.00
Implied upside15.10%
Analyst count7
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell0 / 0
Held by insiders6.79%
Held by institutions60.55%
Institutions holding377
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
16.18
-4.09% from price
SMA 20
16.34
-4.00% from price
SMA 50
16.01
-2.00% from price
SMA 100
15.99
-2.99% from price
SMA 200
15.56
+0.87% from price
EMA 12
16.12
-3.77% from price
EMA 26
16.20
-4.25% from price
EMA 50
16.13
-3.83% from price
RSI (14)
39.2
Neutral
MACD (12,26,9)
-0.08
Hist -0.12
ATR (14)
0.35
2.24% of price
Realised vol 30D
21.7%
Annualised
Bollinger upper
17.09
20, 2σ
Bollinger lower
15.60
20, 2σ
50 / 200 cross
Golden
16.01 vs 15.56
Trend bias
Above 200
+0.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.55
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
21.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.8%
Peak to trough
Max drawdown 5Y
-87.6%
Peak to trough
ATR 14
0.35
2.24% of price
Beta (reported)
1.61
5Y monthly, from filing
Short interest
Shares short
8.58M
Prior 9.62M
Change vs prior
-10.8%
Shorts covering
% of float
7.12%
Normal
% of shares out
6.45%
Against total outstanding
Days to cover
9.2
Crowded exit
Float
129.22M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Dec 3, 25 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Nov 7, 25 | Jefferies | UPGRADE | Hold | Buy |
| Nov 5, 25 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Aug 1, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 16, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 9, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 23, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Feb 22, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 16, 24 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-19
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-04
Tender Offer/Acquisition Reports
SC TO-T/A · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-21
Tender Offer/Acquisition Reports
SC TO-T · 2026-04-13
Corporate Changes & Voting Matters
8-K · 2026-04-03
Headlines
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
Insider Monkey · 21d ago
Immatics and 4 More Stocks See Action From Activist Investors
Barrons.com · 32d ago
LB Pharmaceuticals Names Joseph Miller CFO
MT Newswires · 34d ago
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Insider Monkey · 39d ago
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
Simply Wall St. · 48d ago
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
Simply Wall St. · 48d ago
AUPH Stock Rallies 6% After-Hours — Here’s Why
Stocktwits · 48d ago
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours
MT Newswires · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.